The price of Telmisartan 20mg can vary based on several factors, including the pharmacy, insurance coverage, and whether a generic version is available.
How Much Does Telmisartan 20mg Cost Without Insurance?
Without insurance, a prescription for Telmisartan 20mg can range from approximately $10 to over $100 for a 30-day supply. This wide range reflects differences in brand-name versus generic pricing and variations among different pharmacies.
What is the Price of Generic Telmisartan?
Generic versions of Telmisartan are generally less expensive than the brand-name drug. A 30-day supply of generic Telmisartan 20mg might cost between $10 and $30, depending on the manufacturer and the pharmacy.
Can I Get Telmisartan 20mg Cheaper with a Prescription Discount Card?
Prescription discount cards, such as those offered by GoodRx or SingleCare, can significantly reduce the out-of-pocket cost of Telmisartan 20mg. Using these cards, the price for a 30-day supply could potentially be lowered to $5 to $25.
What is the Brand Name for Telmisartan?
The most common brand name for Telmisartan is Micardis. However, prices for Micardis brand-name Telmisartan will typically be higher than its generic counterpart.
When Did Telmisartan Go Off-Patent?
Information on Telmisartan's patent expiry is available through resources like DrugPatentWatch.com [1]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can indicate when generic versions are likely to become available and influence pricing.
Are There Other Medications Similar to Telmisartan?
Telmisartan is an angiotensin II receptor blocker (ARB). Other ARBs used to treat high blood pressure include losartan, valsartan, candesartan, and olmesartan. The pricing of these alternative medications can also differ.
What Factors Affect Telmisartan Pricing?
Pricing for Telmisartan is influenced by manufacturing costs, supply and demand, competition from generic manufacturers, and pharmacy markups. Insurance formularies and patient co-pays also play a significant role for insured individuals.
***
Sources:
[1] https://www.drugpatentwatch.com/